PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology.
$23.80+1.23%
报价 2026-11-13
市值
$1.37B
EV
$1.2B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -34.1%
$16.69$36.10
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.3x | -2.02 → -1.24 | — |
| FY+32028-12 | 1.6x | -2.02 → -0.89 | — |
毛利率 65% · TTM 收入 $352M · 基数 EPS -2.02（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| PRCTPROCEPT BioRobotics Corporation | $1.37B | +1.2% | +21.1% | 66.3% | – | – | – | |
| TWSTTwist Bioscience Corporation | $7.35B | -2.3% | +20.2% | 53.1% | – | – | – | |
| EWTXEdgewise Therapeutics, Inc. | $4.94B | +0.2% | – | 0% | 4.9x | 4.1x | – | |
| GRDNGuardian Pharmacy Services, Inc. | $3.14B | +0.3% | +0.8% | 23% | 42.4x | 23.8x | 32.9x | |
| CLOVClover Health Investments, Corp. | $2.63B | +1.6% | +56.9% | 17.1% | 292.4x | 162.9x | 20.0x | |
| INSPInspire Medical Systems, Inc. | $1.77B | +0.9% | -5.8% | 85.5% | 14.8x | 22.8x | 17.1x | |
| MESOMesoblast Limited | $1.72B | +1.3% | – | 78.3% | – | – | – | |
| AORTArtivion, Inc. | $931.9M | -1.5% | +10.8% | 61.4% | – | 31.8x | – | |
| QDELQuidelOrtho Corporation | $736.9M | +1.1% | -6.9% | 42.6% | – | 11.5x | – | |
| 同行中位数 | – | – | +5.8% | 47.8% | 28.6x | 23.3x | 20.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $98.3M | $94.5M | $83.1M | $76.4M | $83.3M | $79.2M | $69.2M | $68.2M |
| Gross Margin | 66.3% | 66% | 64.9% | 60.6% | 62.9% | 63.3% | 63.9% | 64% |
| Operating Margin | -27.9% | -29% | -39.2% | -40.6% | -27.8% | -28% | -39.7% | -28.9% |
| Net Income | $-26.5M | $-26.9M | $-31.6M | $-29.8M | $-21.4M | $-19.6M | $-24.7M | $-18.9M |
| Diluted EPS | -0.46 | -0.47 | -0.56 | -0.53 | -0.38 | -0.35 | -0.45 | -0.35 |
| Operating Cash Flow | $-9M | $-57.4M | $-38.1M | $-10.3M | $-6.6M | $-15M | $-17M | $-32.4M |
研究材料
电话会纪要摘要
暂无纪要摘要。